Meta Pixel

News and Announcements

ASMX Ltd are ‘delighted’ to have been admitted on to the GBX Token Sale Platform

  • Published October 25, 2018 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

KEY TAKEAWAYS:

  • ASMX and their token ASM has been admitted on to the GBX Token Sale Platform (GBX-GRID).
  • ASMX were admitted onto the GBX-GRID via the sponsor Firm Kession Capital.
  • The company are delighted to be approved by the GBX-GRID and hope it will help them to grow and develop.

ASMX are delighted to announce that their token ASM, which is the medium of fee exchange on the ASMX system, has been admitted on to the GBX Token Sale Platform (GBX-GRID).

The company were admitted onto the GBX-GRID via the sponsor Firm Kession Capital.

Kession is FCA authorised and they provide ICO and regulatory services to clients across the UK, Europe and Asia.

The GBX-GRID is a robust platform that s becoming very popular as a destination to purchase tokens and make it easier to get involved in the crypto markets.

David Bradley-Ward, CEO of ASMX is ‘delighted’ to have been approved by the GBX.

After spending a considerable amount of time evaluating where ASMX would establish their token sale, he said: “Gibraltar won out to their commitment to this space.

“Coupled with the fact that the GBX is a subsidiary of the Gibraltar Stock Exchange, demonstrated to us that we could rely on the fact that not just any company gets to be featured on the GRID.”

Nick Cowan, CEO of the GBX feels the addition to the platform will help ASMX to grow and develop.

He said: “It is great to see projects like ASMX join us on our journey, as we provide new industry standards for the token space.”

GBX and ASMX share the same ethical approach.

 

About ASMX Ltd

P2P lending has become a large business in a very short space of time, and is set to continue its growth. However, the successful scaling of any market is ‘Access’ and ‘Liquidity’.

ASMX will provide a decentralised blockchain based solution for trading private debt originated by existing and an expanding online lending network that will be accessible to qualifying retail lenders globally.

Register Interest

Capital Insights
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be  Attracting Big Pharma’s Attention

Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.

Capital Insights
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship

From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.

Join over 45,000+ sophisticated investors

Join Now